Cellular therapies are cutting-edge technologies that are now expanding into all spheres of medicine including transplantation. We are increasingly reliant upon marginal or less optimal donor organs for transplantation, however, to close the ever-widening gap between organ demand and supply. Such organs have higher discard rates and less ideal short and longer-term outcomes and ideally require improved organ preservation and resuscitation methods which can be utilised regardless of the jurisdiction. 1 Various cellular therapies are gaining significant momentum as a novel approach to reducing transplant organ ischemia/reperfusion injury (IRI), and potential improvement in graft outcomes. As seen in Figure 1, machine perfusion of organs provides the ideal setting to specifically deliver many targeted therapies to individual grafts, including therapies such as; stem cells, organoids, viral transduction, nanoparticles, and the use of exosome-based treatments. 2 Exosomes are small extracellular vesicles (30-150 nm in diameter), that play a unique role in cellular communication, derived from the endosomal pathway, with intraluminal vesicles being formed in multivesicular bodies and subsequently released with fusion of the plasma membrane. Unlike traditional cell-based therapies, exosomes do not contain live cells, reducing concerns aboutThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.